Major Finding: Irrespective of HPV type, the vaccine reduced the risk for ASCUS by 8%, the risk for LSILs by 14%, and the risk for HSILs by 41%. The risk for CIN2 and CIN3 was 30% and 33% lower than in the control group.
Data Source: Secondary analysis of data on 17,347 women from a phase III efficacy trial in 14 countries.
Disclosures: Dr. Martens has been a consultant for and received research funds, honoraria, and conference sponsorship from Merck & Co. and from GlaxoSmithKline Biologicals, which makes the vaccine and funded the study.
From the Annual Meeting of the American College of Obstetricians and Gynecologists
PREVIEW